Diana Lopez1, Miguel Angel Luque-Fernandez1, Amy Steele1, Gail K Adler1, Alexander Turchin1, Anand Vaidya1. 1. From Brigham and Women's Hospital, Harvard Medical School, Harvard School of Public Health, and Harvard Clinical Research Institute, Boston, Massachusetts; London School of Hygiene & Tropical Medicine, London, United Kingdom; and University of California at Davis School of Medicine, Sacramento, California.
Abstract
BACKGROUND: Benign adrenal tumors are commonly discovered on abdominal imaging. Most are classified as nonfunctional and are considered to pose no health risk, but some are considered functional because they secrete hormones that increase risk for metabolic and cardiovascular diseases. OBJECTIVE: To evaluate the hypothesis that nonfunctional adrenal tumors (NFATs) increase risk for cardiometabolic outcomes compared with absence of adrenal tumors. DESIGN: Cohort study. SETTING: Integrated hospital system. PARTICIPANTS: Participants with benign NFATs ("exposed"; n = 166) and those with no adrenal tumor ("unexposed"; n = 740), with at least 3 years of follow-up. MEASUREMENTS: Medical records were reviewed from the time of abdominal imaging for development of incident outcomes (hypertension, composite diabetes [prediabetes or type 2 diabetes], hyperlipidemia, cardiovascular events, and chronic kidney disease) (mean, 7.7 years). Primary analyses evaluated independent associations between exposure status and incident outcomes by using adjusted generalized linear models. Secondary analyses evaluated relationships between NFATs and cortisol physiology. RESULTS: Participants with NFATs had significantly higher risk for incident composite diabetes than those without adrenal tumors (30 of 110 [27.3%] vs. 72 of 615 [11.7%] participants; absolute risk, 15.6% [95% CI, 6.9% to 24.3%]; adjusted risk ratio, 1.87 [CI, 1.17 to 2.98]). No significant associations between NFATs and other outcomes were observed. Higher "normal" postdexamethasone cortisol levels (≤50 nmol/L) were associated with larger NFAT size and higher prevalence of type 2 diabetes. LIMITATION: Potential bias in the selection of participants and ascertainment of outcomes. CONCLUSION: Participants with NFATs had a significantly higher risk for diabetes than those without adrenal tumors. These results should prompt a reassessment of whether the classification of benign adrenal tumors as "nonfunctional" adequately reflects the continuum of hormone secretion and metabolic risk they may harbor. PRIMARY FUNDING SOURCE: National Institutes of Health and Doris Duke Charitable Foundation.
BACKGROUND: Benign adrenal tumors are commonly discovered on abdominal imaging. Most are classified as nonfunctional and are considered to pose no health risk, but some are considered functional because they secrete hormones that increase risk for metabolic and cardiovascular diseases. OBJECTIVE: To evaluate the hypothesis that nonfunctional adrenal tumors (NFATs) increase risk for cardiometabolic outcomes compared with absence of adrenal tumors. DESIGN: Cohort study. SETTING: Integrated hospital system. PARTICIPANTS: Participants with benign NFATs ("exposed"; n = 166) and those with no adrenal tumor ("unexposed"; n = 740), with at least 3 years of follow-up. MEASUREMENTS: Medical records were reviewed from the time of abdominal imaging for development of incident outcomes (hypertension, composite diabetes [prediabetes or type 2 diabetes], hyperlipidemia, cardiovascular events, and chronic kidney disease) (mean, 7.7 years). Primary analyses evaluated independent associations between exposure status and incident outcomes by using adjusted generalized linear models. Secondary analyses evaluated relationships between NFATs and cortisol physiology. RESULTS: Participants with NFATs had significantly higher risk for incident composite diabetes than those without adrenal tumors (30 of 110 [27.3%] vs. 72 of 615 [11.7%] participants; absolute risk, 15.6% [95% CI, 6.9% to 24.3%]; adjusted risk ratio, 1.87 [CI, 1.17 to 2.98]). No significant associations between NFATs and other outcomes were observed. Higher "normal" postdexamethasone cortisol levels (≤50 nmol/L) were associated with larger NFAT size and higher prevalence of type 2 diabetes. LIMITATION: Potential bias in the selection of participants and ascertainment of outcomes. CONCLUSION: Participants with NFATs had a significantly higher risk for diabetes than those without adrenal tumors. These results should prompt a reassessment of whether the classification of benign adrenal tumors as "nonfunctional" adequately reflects the continuum of hormone secretion and metabolic risk they may harbor. PRIMARY FUNDING SOURCE: National Institutes of Health and Doris Duke Charitable Foundation.
Authors: R Rossi; L Tauchmanova; A Luciano; M Di Martino; C Battista; L Del Viscovo; V Nuzzo; G Lombardi Journal: J Clin Endocrinol Metab Date: 2000-04 Impact factor: 5.958
Authors: S Bovio; A Cataldi; G Reimondo; P Sperone; S Novello; A Berruti; P Borasio; C Fava; L Dogliotti; G V Scagliotti; A Angeli; M Terzolo Journal: J Endocrinol Invest Date: 2006-04 Impact factor: 4.256
Authors: F Mantero; M Terzolo; G Arnaldi; G Osella; A M Masini; A Alì; M Giovagnetti; G Opocher; A Angeli Journal: J Clin Endocrinol Metab Date: 2000-02 Impact factor: 5.958
Authors: Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin Journal: J Clin Endocrinol Metab Date: 2015-07-29 Impact factor: 5.958
Authors: Wiebke Arlt; Michael Biehl; Angela E Taylor; Stefanie Hahner; Rossella Libé; Beverly A Hughes; Petra Schneider; David J Smith; Han Stiekema; Nils Krone; Emilio Porfiri; Giuseppe Opocher; Jerôme Bertherat; Franco Mantero; Bruno Allolio; Massimo Terzolo; Peter Nightingale; Cedric H L Shackleton; Xavier Bertagna; Martin Fassnacht; Paul M Stewart Journal: J Clin Endocrinol Metab Date: 2011-09-14 Impact factor: 5.958
Authors: M P de Paula; A B Moraes; M das Graças Coelho de Souza; E M R Cavalari; R C Campbell; G da Silva Fernandes; M L F Farias; L M C Mendonça; M Madeira; E Bouskela; L G Kraemer-Aguiar; L Vieira Neto Journal: J Endocrinol Invest Date: 2020-07-19 Impact factor: 4.256
Authors: Marta Araujo-Castro; Pablo Valderrábano; Héctor F Escobar-Morreale; Felicia A Hanzu; Gregori Casals Journal: Endocrine Date: 2020-11-21 Impact factor: 3.633